CrownBio offers a collection large enough to be representative of the histological and genetic diversity seen in the patient population in ongoing clinical trials.
CrownBio’s newly established models have been trialed with a range of EGFR inhibitors – including I, II, and III generation TKIs as well as Erbitux® – and their poor response to therapy mirrors the...
Receive JSR Life Sciences news on your RSS reader.